Background
Expression and mutation landscape of Mucins in NSCLC
Cancer | A | B | Neither | A Not B | B Not A | Both | Log2 Odds Ratio | p-Value | q-Value | Tendency |
---|---|---|---|---|---|---|---|---|---|---|
LUAD | MUC2 | MUC16 | 404 | 21 | 265 | 38 | 1.464 | < 0.001 | 0.003 | Co-occurrence |
MUC3A | MUC16 | 421 | 4 | 284 | 19 | 2.816 | < 0.001 | < 0.001 | Co-occurrence | |
MUC5B | MUC16 | 395 | 30 | 244 | 59 | 1.671 | < 0.001 | < 0.001 | Co-occurrence | |
MUC12 | MUC17 | 580 | 0 | 137 | 11 | > 3 | < 0.001 | < 0.001 | Co-occurrence | |
MUC16 | MUC17 | 368 | 212 | 57 | 91 | 1.471 | < 0.001 | < 0.001 | Co-occurrence | |
MUC2 | MUC17 | 542 | 38 | 127 | 21 | 1.238 | 0.003 | 0.032 | Co-occurrence | |
MUC5B | MUC17 | 521 | 59 | 118 | 30 | 1.167 | 0.001 | 0.013 | Co-occurrence | |
MUC3A | MUC20 | 687 | 19 | 18 | 4 | > 3 | 0.004 | 0.035 | Co-occurrence | |
MUC4 | MUC20 | 663 | 43 | 1 | 21 | > 3 | < 0.001 | < 0.001 | Co-occurrence | |
MUC21 | MUC22 | 712 | 10 | 0 | 6 | > 3 | < 0.001 | < 0.001 | Co-occurrence | |
MUC2 | MUC5B | 599 | 40 | 70 | 19 | 2.023 | < 0.001 | < 0.001 | Co-occurrence | |
MUC5B | MUC6 | 620 | 79 | 19 | 10 | 2.046 | 0.001 | 0.014 | Co-occurrence | |
MUC3A | MUC7 | 681 | 14 | 24 | 9 | > 3 | < 0.001 | < 0.001 | Co-occurrence | |
LUSC | MUC4 | MUC20 | 306 | 18 | 5 | 140 | > 3 | < 0.001 | < 0.001 | Co-occurrence |
MUC12 | MUC17 | 373 | 0 | 76 | 20 | > 3 | < 0.001 | < 0.001 | Co-occurrence | |
MUC21 | MUC22 | 456 | 9 | 0 | 4 | > 3 | < 0.001 | < 0.001 | Co-occurrence |
Effects of Mucins on cellular signaling pathways
Regulation of the expression of Mucin family genes
The importance of Mucin for the tumor immune microenvironment
Mucins and therapeutic perspectives
Drug Name | Clinical trial ID | Phase | Clinical trial |
---|---|---|---|
TG4010+ chemotherapy | NCT00415818 | Phase 2/3 | A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer |
TG4010 + placebo | NCT01383148 | Phase 2/3 | A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy with or Without TG4010 Immunotherapy Product in Patients with Stage IV NSCLC |
TG4010 + Nivolumab | NCT02823990 | Phase 2 | Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients with Metastatic NSCLC |
TG4010 + Nivolumab | NCT03353675 | Phase 2 | A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined with TG4010 and Nivolumab in Patients with Advanced Non-squamous NSCLC |
Tecemotide (L-BLP25) | NCT00157196 | Phase 2 | A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in NSCLC Patients with Unresectable Stage III Disease |
Tecemotide (L-BLP25) | NCT00157209 | Phase 2 | A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of NSCLC |
Tecemotide | NCT00409188 | Phase 3 | A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in NSCLC Subjects with Unresectable Stage III Disease. |
Tecemotide (L-BLP25) | NCT01015443 | Phase 3 | A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects with Stage III, Unresectable, NSCLC Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy |
Tecemotide | NCT02049151 | Phase 3 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects with Completed Concurrent Chemo-radiotherapy for Unresectable Stage III NSCLC |
Tecemotide | NCT00960115 | Phase 1/2 | Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects with Stage III Unresectable Non-Small Cell Lung Cancer Following Primary Chemoradiotherapy |
Tecemotide+Bevacizumab | NCT00828009 | Phase 2 | A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation |
Tecemotide | NCT01423760 | Not Applicable | An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials |
ETBX-051+ ETBX-061+ ETBX-011 | NCT02140996 | Phase 1 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People with Advanced Cancer |
anti-MUC1 CAR T cells | NCT03525782 | Phase 1/2 | A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients with Advanced Non-small Cell Lung Cancer |
anti-MUC1 CAR-pNK cells | NCT02839954 | Phase 1/2 | Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor |
anti-MUC1 CAR T cells | NCT02587689 | Phase 1/2 | Phase I/II Study of Anti-MUC1 CAR T Cells for Patients with MUC1+ Advanced Refractory Solid Tumor |
CART-TnMUC1–01 | NCT04025216 | Phase 1 | A Study of CART-TnMUC1 in Patients with TnMUC1-Positive Advanced Cancers |
MUC1 Peptide-Poly-ICLC | NCT03300817 | Phase 1 | A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer |
MUC1 peptide-poly-ICLC | NCT01720836 | Phase 1/2 | Vaccine Therapy in Treating Patients with Stage I-III Non-Small Cell Lung Cancer |